Wazodylatacyjne β-adrenolityki w leczeniu nadciśnienia tętniczego – przykład nebiwololu Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2014
Słowa kluczowe:
nadciśnienie tętnicze, tlenek azotu, rozszerzanie naczyń, nebiwolol
##plugins.themes.bootstrap3.article.main##
Abstrakt
W terapii nadciśnienia tętniczego dysponujemy pięcioma podstawowymi grupami leków: β-adrenolitykami, antagonistami wapnia, inhibitorami enzymu konwertującego angiotensynę, antagonistami receptorów dla angiotensyny i diuretykami. W skład każdej z tych grup wchodzi co najmniej kilka cząsteczek, które mimo podobnego głównego mechanizmu działania różnią się między sobą w zakresie dodatkowych właściwości. Dodatkowe cechy cząsteczek pozwalają spersonalizować terapię hipotensyjną w zależności od profilu pacjenta. W przypadku β-adrenolityków cząsteczką o dodatkowych właściwościach jest nebiwolol. Mimo że lek obniża ciśnienie tętnicze w podobnym stopniu jak konwencjonalne β-adrenolityki i inne leki hipotensyjne, dodatkowo działa naczyniorozszerzająco za pośrednictwem tlenku azotu.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Balsam , P., & Grabowski , M. (2014). Wazodylatacyjne β-adrenolityki w leczeniu nadciśnienia tętniczego – przykład nebiwololu. Medycyna Faktów , 7(4(25), 85-91. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2344
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Van Nueten L., De Cree J.: Nebivolol: comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure. Cardiovascular drugs and therapy 1998; 12(4): 339-44.
2. Toblli J.E., DiGennaro F., Giani J.F. et al.: Nebivolol: impact on cardiac and endothelial function and clinical utility. Vascular health and risk management. 2012; 8: 151-60.
3. Van de Water A., Janssens W., Van Neuten J. et al.: Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. Journal of cardiovascular pharmacology 1988; 11(5): 552-63.
4. Sorrentino S.A., Doerries C., Manes C. et al.: Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional beta1-blockade. Journal of the American College of Cardiology 2011; 57(5): 601-11.
5. McEniery C.M., Schmitt M., Qasem A. et al.: Nebivolol increases arterial distensibility in vivo. Hypertension 2004; 44(3): 305-10.
6. Makolkin V.I., Akhmedova O.O., Buval’tsev V.I. et al. [Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease associated with type 2 diabetes]. Kardiologiia 2003; 43(2): 40-3.
7. Rizos E., Bairaktari E., Kostoula A. et al.: The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. Journal of cardiovascular pharmacology and therapeutics 2003; 8(2): 127-34.
8. Agabiti Rosei E., Rizzoni D.: Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007; 67(8): 1097-107.
9. Marazzi G., Volterrani M., Caminiti G. et al.: Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients. Advances in therapy 2010; 27(9): 655-64.
10. Cleophas T.J., Agrawal R., Lichtenthal A. et al.: Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients. American journal of therapeutics 2006; 13(3): 192-7.
11. Mazza A., Gil-Extremera B., Maldonato A. et al.: Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood pressure 2002; 11(3): 182-8.
12. Grassi G., Trevano F.Q., Facchini A. et al.: Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood pressure Supplement 2003; 2: 35-40.
13. Munzel T., Gori T.: Nebivolol: the somewhat-different beta-adrenergic receptor blocker. Journal of the American College of Cardiology 2009; 54(16): 1491-9.
14. Ambrosioni E., Bacchelli S., Esposti D.D. et al.: Beta-blockade in hypertension and congestive heart failure. Journal of cardiovascular pharmacology 2001; 38(Suppl. 3): S25-31.
15. Van Bortel L.M., Fici F., Mascagni F.: Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. American journal of cardiovascular drugs: drugs, devices, and other interventions 2008; 8(1): 35-44.
16. Czuriga I., Riecansky I., Bodnar J. et al.: Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovascular drugs and therapy 2003; 17(3): 257-63.
17. Poirier L., Cleroux J., Nadeau A. et al.: Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. Journal of hypertension 2001; 19(8): 1429-35.
18. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. Journal of hypertension 2013; 31(10): 1925-38.
19. Levine H.J.: Rest heart rate and life expectancy. Journal of the American College of Cardiology 1997; 30(4): 1104-6.
20. Kasprzak J.D., Stepinska J., Wozakowska Kaplon B. et al. [Optimum heart rate – the current goal of cardiovascular therapy. Position statement of the Polish Cardiac Society Working Group on Cardiovascular Drug Therapy]. Kardiologia polska 2012; 70(10): 1081-94.
21. Filipiak K., Tykarski A., Czarnecka D. et al.: Miejsce wazodylatacyjnych leków beta-adrenolitycznych w terapii nadciśnienia tętniczego i jego powikłań sercowo-naczyniowych. Stanowisko ekspertów. Nadciśnienie tętnicze 2010: 13.
22. Flather M.D., Shibata M.C., Coats A.J. et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European heart journal 2005; 26(3): 215-25.
23. Ghio S., Magrini G., Serio A. et al.: Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European heart journal 2006; 27(5): 562-8.
24. Dobre D., van Veldhuisen D.J., Mordenti G. et al.: Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. American heart journal 2007; 154(1): 109-15.
25. Gao Y.S., Nagao T., Bond R.A. et al.: Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. Journal of cardiovascular pharmacology 1991; 17(6): 964-9.
26. Wilkinson I.B., MacCallum H., Flint L. et al.: The influence of heart rate on augmentation index and central arterial pressure in humans. The Journal of physiology 2000; 525 Pt 1: 263-70.
27. Morgan T., Lauri J., Bertram D. et al.: Effect of different antihypertensive drug classes on central aortic pressure. American journal of hypertension 2004; 17(2): 118-23.
28. London G.M., Asmar R.G., O’Rourke M.F. et al., RP investigators: Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. Journal of the American College of Cardiology 2004; 43(1): 92-9.
29. Williams B., Lacy P.S., Thom S.M. et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113(9): 1213-25.
30. Agabiti-Rosei E., Porteri E., Rizzoni D.: Arterial stiffness, hypertension, and rational use of nebivolol. Vascular health and risk management 2009; 5(1): 353-60.
31. Dhakam Z., Yasmin, McEniery C.M. et al.: Comparison of atenolol and nebivolol in isolated systolic hypertension. Journal of hypertension 2008; 26(2): 351-6.
32. Mahmud A., Feely J.: Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. American journal of hypertension 2008; 21(6): 663-7.
33. Kampus P., Serg M., Kals J. et al.: Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension 2011; 57(6): 1122-8.
34. Jabbour A., Macdonald P.S., Keogh A.M. et al.: Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. Journal of the American College of Cardiology 2010; 55(17): 1780-7.
35. Studinger P., Tabak A.G., Chen C.H. et al.: The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial. Journal of clinical hypertension 2013; 15(12): 910-7.
36. Stoschitzky K., Stoschitzky G., Brussee H. et al.: Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology 2006; 106(4): 199-206.
37. Yilmaz M.B., Erdem A., Yalta K. et al.: Impact of beta-blockers on sleep in patients with mild hypertension: a randomized trial between nebivolol and metoprolol. Advances in therapy 2008; 25(9): 871-83.
38. Cordero A., Bertomeu-Martinez V., Mazon P. et al.: Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents. Cardiovascular therapeutics 2010; 28(1): 15-22.
39. Van Bortel L.M., Bulpitt C.J., Fici F.: Quality of life and antihypertensive effect with nebivolol and losartan. American journal of hypertension 2005; 18(8): 1060-6.
2. Toblli J.E., DiGennaro F., Giani J.F. et al.: Nebivolol: impact on cardiac and endothelial function and clinical utility. Vascular health and risk management. 2012; 8: 151-60.
3. Van de Water A., Janssens W., Van Neuten J. et al.: Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. Journal of cardiovascular pharmacology 1988; 11(5): 552-63.
4. Sorrentino S.A., Doerries C., Manes C. et al.: Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional beta1-blockade. Journal of the American College of Cardiology 2011; 57(5): 601-11.
5. McEniery C.M., Schmitt M., Qasem A. et al.: Nebivolol increases arterial distensibility in vivo. Hypertension 2004; 44(3): 305-10.
6. Makolkin V.I., Akhmedova O.O., Buval’tsev V.I. et al. [Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease associated with type 2 diabetes]. Kardiologiia 2003; 43(2): 40-3.
7. Rizos E., Bairaktari E., Kostoula A. et al.: The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. Journal of cardiovascular pharmacology and therapeutics 2003; 8(2): 127-34.
8. Agabiti Rosei E., Rizzoni D.: Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007; 67(8): 1097-107.
9. Marazzi G., Volterrani M., Caminiti G. et al.: Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients. Advances in therapy 2010; 27(9): 655-64.
10. Cleophas T.J., Agrawal R., Lichtenthal A. et al.: Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients. American journal of therapeutics 2006; 13(3): 192-7.
11. Mazza A., Gil-Extremera B., Maldonato A. et al.: Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood pressure 2002; 11(3): 182-8.
12. Grassi G., Trevano F.Q., Facchini A. et al.: Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood pressure Supplement 2003; 2: 35-40.
13. Munzel T., Gori T.: Nebivolol: the somewhat-different beta-adrenergic receptor blocker. Journal of the American College of Cardiology 2009; 54(16): 1491-9.
14. Ambrosioni E., Bacchelli S., Esposti D.D. et al.: Beta-blockade in hypertension and congestive heart failure. Journal of cardiovascular pharmacology 2001; 38(Suppl. 3): S25-31.
15. Van Bortel L.M., Fici F., Mascagni F.: Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. American journal of cardiovascular drugs: drugs, devices, and other interventions 2008; 8(1): 35-44.
16. Czuriga I., Riecansky I., Bodnar J. et al.: Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovascular drugs and therapy 2003; 17(3): 257-63.
17. Poirier L., Cleroux J., Nadeau A. et al.: Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. Journal of hypertension 2001; 19(8): 1429-35.
18. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. Journal of hypertension 2013; 31(10): 1925-38.
19. Levine H.J.: Rest heart rate and life expectancy. Journal of the American College of Cardiology 1997; 30(4): 1104-6.
20. Kasprzak J.D., Stepinska J., Wozakowska Kaplon B. et al. [Optimum heart rate – the current goal of cardiovascular therapy. Position statement of the Polish Cardiac Society Working Group on Cardiovascular Drug Therapy]. Kardiologia polska 2012; 70(10): 1081-94.
21. Filipiak K., Tykarski A., Czarnecka D. et al.: Miejsce wazodylatacyjnych leków beta-adrenolitycznych w terapii nadciśnienia tętniczego i jego powikłań sercowo-naczyniowych. Stanowisko ekspertów. Nadciśnienie tętnicze 2010: 13.
22. Flather M.D., Shibata M.C., Coats A.J. et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European heart journal 2005; 26(3): 215-25.
23. Ghio S., Magrini G., Serio A. et al.: Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European heart journal 2006; 27(5): 562-8.
24. Dobre D., van Veldhuisen D.J., Mordenti G. et al.: Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. American heart journal 2007; 154(1): 109-15.
25. Gao Y.S., Nagao T., Bond R.A. et al.: Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. Journal of cardiovascular pharmacology 1991; 17(6): 964-9.
26. Wilkinson I.B., MacCallum H., Flint L. et al.: The influence of heart rate on augmentation index and central arterial pressure in humans. The Journal of physiology 2000; 525 Pt 1: 263-70.
27. Morgan T., Lauri J., Bertram D. et al.: Effect of different antihypertensive drug classes on central aortic pressure. American journal of hypertension 2004; 17(2): 118-23.
28. London G.M., Asmar R.G., O’Rourke M.F. et al., RP investigators: Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. Journal of the American College of Cardiology 2004; 43(1): 92-9.
29. Williams B., Lacy P.S., Thom S.M. et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113(9): 1213-25.
30. Agabiti-Rosei E., Porteri E., Rizzoni D.: Arterial stiffness, hypertension, and rational use of nebivolol. Vascular health and risk management 2009; 5(1): 353-60.
31. Dhakam Z., Yasmin, McEniery C.M. et al.: Comparison of atenolol and nebivolol in isolated systolic hypertension. Journal of hypertension 2008; 26(2): 351-6.
32. Mahmud A., Feely J.: Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. American journal of hypertension 2008; 21(6): 663-7.
33. Kampus P., Serg M., Kals J. et al.: Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension 2011; 57(6): 1122-8.
34. Jabbour A., Macdonald P.S., Keogh A.M. et al.: Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. Journal of the American College of Cardiology 2010; 55(17): 1780-7.
35. Studinger P., Tabak A.G., Chen C.H. et al.: The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial. Journal of clinical hypertension 2013; 15(12): 910-7.
36. Stoschitzky K., Stoschitzky G., Brussee H. et al.: Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology 2006; 106(4): 199-206.
37. Yilmaz M.B., Erdem A., Yalta K. et al.: Impact of beta-blockers on sleep in patients with mild hypertension: a randomized trial between nebivolol and metoprolol. Advances in therapy 2008; 25(9): 871-83.
38. Cordero A., Bertomeu-Martinez V., Mazon P. et al.: Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents. Cardiovascular therapeutics 2010; 28(1): 15-22.
39. Van Bortel L.M., Bulpitt C.J., Fici F.: Quality of life and antihypertensive effect with nebivolol and losartan. American journal of hypertension 2005; 18(8): 1060-6.